Quantcast
Home > Quotes > MACK
MACK

Merrimack Pharmaceuticals, Inc. Common Stock (MACK) Quote & Summary Data

$4.51
*  
0.03
0.66%
Get MACK Alerts
*Delayed - data as of Nov. 21, 2018 10:29 ET  -  Find a broker to begin trading MACK now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MACK Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.37 / $ 4.53
Today's High / Low
$ 4.54 / $ 4.27
Share Volume
5,865
50 Day Avg. Daily Volume
111,923
Previous Close
$ 4.54
52 Week High / Low
$ 12.45 / $ 3.3401
Market Cap
60,175,956
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
5,865
50 Day Avg. Daily Volume:
111,923

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.25

Trading Range

The current last sale of $4.51 is 35.03% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.54 $ 12.45
 Low: $ 4.27 $ 3.3401

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer by targeting biomarker-defined cancers. Our vision is to ensure that cancer patients and their families live fulfilling lives. Our mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of our development programs, including four clinical trials and six candidates in preclinical development, fit into our strategy of (1) understanding the biological problems we are trying to solve, (2) designing specific solutions against the problems we are trying to solve and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. We currently own worldwide development and commercial rights to all of our clinical and preclinical programs.  ... More ...  


Risk Grade

Where does MACK fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.54
Open Date:
Nov. 21, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x